ILMN vs QGEN
ILMN: Illumina provides the essential genetic sequencing and array platforms that power modern genomic research and clinical diagnostics. QGEN: QIAGEN provides essential sample-to-insight technologies that empower researchers and clinicians to unlock molecular and genetic information from biological samples.
Side-by-side fundamentals
| Metric | ILMN | QGEN | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $191.79 | $43.85 | |
| Market cap as of 2026-08-11 | $29.0B | $9.1B | |
| P/E as of 2026-08-11 | 34.92 | 22.56 | QGEN lower |
| PEG as of 2026-08-11 | 3.62 | 3.48 | QGEN lower |
| Net margin as of 2026-08-11 | +18.4% | +19.2% | QGEN higher |
| Gross margin as of 2026-08-11 | +66.4% | +62.6% | ILMN higher |
| Operating margin as of 2026-08-11 | +19.5% | +20.7% | QGEN higher |
| ROE as of 2026-08-11 | +31.1% | +11.3% | ILMN higher |
| ROA as of 2026-08-11 | +12.7% | +6.6% | ILMN higher |
| Debt / equity as of 2026-08-11 | 0.70 | 0.49 | QGEN lower |
| Revenue growth (YoY) as of 2026-08-11 | +4.9% | +4.8% | ILMN higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | -0.8% | QGEN higher |
| Dividend yield as of 2026-08-11 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-08-11 | 1.43 | 0.62 | |
| 1-year return as of 2026-08-10 close | +102.8% | -8.7% | ILMN higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.